New drug combo targets Hard-to-Treat cancers with gene mutation
NCT ID NCT06496568
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 33 times
Summary
This early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see if the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BC Cancer Vancouver Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Vanderbilt-Ingram Cancer Ctr
Nashville, Tennessee, 37232, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.